(16797697), S. L., (16797700), S. D. P., (16797703), L. E. O., (16375918), E. G., (16797706), J. P. B., (15135437), D. W., . . . (14940894), T. J. P. (2025). Supplementary Table S2 from Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression.
Chicago (17e ed.) Bronvermelding(16797697), Stephanie Lheureux, et al. Supplementary Table S2 from Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression. 2025.
MLA (9e ed.) Bronvermelding(16797697), Stephanie Lheureux, et al. Supplementary Table S2 from Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression. 2025.